Answers are grounded in this paper and cite their sources.
Uncovers high-specificity DNA aptamers targeting HPV16 E6, suggesting potential for cervical cancer treatment.
High Resolution Image Download MS PowerPoint Slide HPV16 E6 oncoprotein is a critical driver of cervical cancer, necessitating high-specificity diagnostic and therapeutic agents. This study presents an in silico selection of DNA aptamers targeting the HPV16 E6 oncoprotein through a pipeline of structure-based virtual screening and 250 ns Molecular Dynamics (MD) simulations, performed with GROMACS 2019 and the CHARMM36M. Using AutoDock VinaXB and HADDOCK, eight candidates were evaluated against the F2 RNA benchmark. MM/PBSA calculations identified Apt 9 (−143.76 kcal/mol) as the most potent lead, surpassing the affinity of the F2 control (−142.80 kcal/mol). Apt 8 emerged as a key consensus lead, exhibiting superior structural stability (RMSD 0.23 nm) and the most robust interaction network (11.49 hydrogen bonds). Notably, these leads primarily target critical Histidine residues (His78, His118, and His126) on the E6 protein. These results designate Apt 9 and Apt 8 as high-priority candidates for experimental validation, providing a robust theoretical foundation for novel HPV16-targeted interventions.
No takes yet. Share an insight, caveat, or question.
Phathekile et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: